- Home
- CALC vs FGEN Comparison
CALC vs FGEN Comparison
Compare CALC & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- FGEN
- Stock Information
- Founded
- CALC 2011
- FGEN 1993
- Country
- CALC United States
- FGEN United States
- Employees
- CALC N/A
- FGEN N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- CALC Health Care
- FGEN Health Care
- Exchange
- CALC Nasdaq
- FGEN Nasdaq
- Market Cap
- CALC 40.3M
- FGEN 34.5M
- IPO Year
- CALC N/A
- FGEN 2014
- Fundamental
- Price
- CALC $2.76
- FGEN $0.40
- Analyst Decision
- CALC Strong Buy
- FGEN
- Analyst Count
- CALC 5
- FGEN 0
- Target Price
- CALC $18.20
- FGEN N/A
- AVG Volume (30 Days)
- CALC 71.7K
- FGEN 996.1K
- Earning Date
- CALC 11-13-2024
- FGEN 11-12-2024
- Dividend Yield
- CALC N/A
- FGEN N/A
- EPS Growth
- CALC N/A
- FGEN N/A
- EPS
- CALC N/A
- FGEN N/A
- Revenue
- CALC N/A
- FGEN $180,015,000.00
- Revenue This Year
- CALC N/A
- FGEN $19.67
- Revenue Next Year
- CALC N/A
- FGEN N/A
- P/E Ratio
- CALC N/A
- FGEN N/A
- Revenue Growth
- CALC N/A
- FGEN 16.15
- 52 Week Low
- CALC $2.05
- FGEN $0.18
- 52 Week High
- CALC $8.38
- FGEN $2.93
- Technical
- Relative Strength Index (RSI)
- CALC 34.02
- FGEN 58.65
- Support Level
- CALC $2.67
- FGEN $0.34
- Resistance Level
- CALC $2.90
- FGEN $0.37
- Average True Range (ATR)
- CALC 0.26
- FGEN 0.04
- MACD
- CALC 0.00
- FGEN -0.00
- Stochastic Oscillator
- CALC 50.35
- FGEN 76.07
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.